Humacyte alternatives
8 products to explore · 2026
Your shortlist, at a glance.
Read the comparisons ↓| Product | Pricing | Explore |
|---|---|---|
 Trestle BiotherapeuticsBioengineered kidneys for patients with kidney failure | See website | Compare |
 CELLINKLeading the way in 3D bioprinting with bioprinters and bioinks | See website | Compare |
 DaVitaDialysis services, kidney education, and support for CKD and ESKD patients | See website | Compare |
| FFresenius Medical CareInnovative products and therapies for kidney dialysis and apheresis patients. | See website | Compare |
 Miromatrix MedicalHealthcare & Medical | See website | Compare |
 OrganovoPioneering 3D Human Tissues for Drug Discovery | See website | Compare |
 United TherapeuticsUnited Therapeutics | See website | Compare |
| VVericelVericel | See website | Compare |
Check each product’s website for current pricing and features. A verified badge indicates a verified listing, not a ranking.
About Humacyte and its alternatives
Users searching for Humacyte alternatives are typically clinicians, hospital procurement teams, or researchers evaluating options for vascular trauma repair, hemodialysis access, or peripheral arterial disease. Humacyte’s Symvess offers a first-in-class biologic vessel that becomes the patient’s own tissue after implantation. Alternatives range from traditional synthetic ePTFE and Dacron grafts to other regenerative or xenograft products. These options differ in infection resistance, long-term durability, regulatory status, and suitability for urgent trauma cases versus elective procedures. Decision-makers compare reoperation rates, handling characteristics, and availability when synthetic grafts have failed or infection risk is high. Understanding these trade-offs helps teams select the right conduit based on patient anatomy, urgency, and long-term outcomes rather than defaulting to legacy materials.
Explore the alternatives
1.Trestle Biotherapeutics
Healthcare & MedicalBioengineered kidneys for patients with kidney failure
2.CELLINK
Healthcare & MedicalLeading the way in 3D bioprinting with bioprinters and bioinks
3.DaVita
Healthcare & MedicalDialysis services, kidney education, and support for CKD and ESKD patients
- F
4.Fresenius Medical Care
Healthcare & MedicalInnovative products and therapies for kidney dialysis and apheresis patients.
5.Miromatrix Medical
Healthcare & Medical6.Organovo
Healthcare & MedicalPioneering 3D Human Tissues for Drug Discovery
7.United Therapeutics
Healthcare & MedicalUnited Therapeutics
- V
8.Vericel
Healthcare & MedicalVericel
See more comparisons in Healthcare & Medical alternatives.
Questions about Humacyte alternatives
What are the best Humacyte Symvess alternatives for emergency vascular trauma when biologic grafts are unavailable?
Surgeons often turn to ePTFE grafts from W.L. Gore or cryopreserved allografts when immediate off-the-shelf biologic options like Symvess are not stocked. These alternatives provide rapid availability but carry higher infection and thrombosis risks compared with Humacyte’s regenerative approach.
How does Humacyte compare to synthetic grafts for AV access in dialysis patients?
Humacyte’s ATEV has shown lower infection rates and better integration in phase 3 trials versus standard ePTFE. Synthetic grafts remain cheaper and more widely available but require more revisions over time.
Are there regenerative medicine companies offering similar acellular vessels to Humacyte?
Companies such as Organogenesis and Integra LifeSciences provide acellular biologic matrices, yet none currently market an FDA-approved vascular conduit matching Symvess indications for trauma.
What factors should hospitals consider when choosing between Humacyte and traditional Dacron grafts?
Key considerations include infection rates, handling in contaminated fields, long-term remodeling potential, and total cost of care including reinterventions. Humacyte’s product aims to reduce these downstream costs through regeneration.
Is Humacyte the only company with an approved tissue-engineered vessel for vascular trauma?
As of late 2024, Symvess holds the first FDA approval for a completely biologic acellular vessel in this indication; competing products remain either synthetic or limited to investigational or non-vascular uses.
How do pricing and reimbursement differ for Humacyte versus legacy vascular grafts?
Humacyte’s biologic product carries premium pricing typical of novel regenerative therapies, while synthetic grafts are commoditized. Reimbursement pathways are still evolving for the new category.